How precise can gene editing be? Will researchers succeed in extending the “healthspan” of people’s lives? Can telehealth provide responsible mental health care? Do firewalkers hold the key to easing pain?
Some of the world’s top biotech researchers, public health experts, and industry executives took on these questions and more at our 2022 STAT Summit, held in Boston. The event featured biochemist David Liu, winner of STAT’s 2022 Biomedical Innovation Award, talking about the possibilities and limits of CRISPR treatments. Anthony Fauci, retiring after nearly four decades as head of National Institute of Allergy and Infectious Diseases, described how his responses to Trump during the Covid-19 pandemic turned him into “public enemy No. 1.” And Altos Labs’ Hal Barron and Juan Carlos Izpisua Belmonte defended their ambitious project to reverse disease, saying that if it succeeds, it will “rewrite textbooks.” Interviews with top executives of Merck, Pfizer, Vertex and other companies, along with sessions on why there aren’t more Black doctors and the impacts of the U.S. Supreme Court’s Dobbs decision, rounded out the program.
The Summit’s offerings underscored both the transformative power of new technologies and the formidable challenges of this complex and fast-changing era, a perspective that we hope is captured in this e-book of collected articles.
Publication date: January 2023
Print length: 69 pages
File size: 4 MB
File format: PDF
Language: English
Enter the information below to begin your free e-book download
About the sponsor
About the sponsor
Genentech’s journey started with a big question: Can genetic engineering technology revolutionize medicine? What seemed improbable – or at least very premature – at the time soon became the ambitious goal of our founders, the mission of our company, and the beginning of the biotechnology industry. More than four decades later, the answer to that question – and to the countless others that followed it – has transformed and extended the lives of so many patients with serious and life-threatening medical conditions. But as long as people continue to suffer from diseases like cancer and multiple sclerosis, there is still much more to do. And the obstacles that remain are arguably the toughest ones to overcome. We believe the opportunity for the greatest impact starts with the challenge set by the boldest question. So today we’re pushing even harder and asking even bigger questions of ourselves, our industry and society. How can we ensure that all patients benefit from medical innovation? How can we advance from treating to curing, or even reversing the impact of disease? How can we intervene in early childhood to address traumas that can lead to serious illnesses later in life? We’re passionate about finding the answers to all of these and more – both in the work we do and through critical partnerships and collaborations beyond our walls. Join us in examining some of the biggest questions in healthcare.